(COMING SOON) Unitaid has allocated more than £6 million in new investment to the University of Liverpool-led LONGEVITY task, which aims to improve long-acting remedies for tuberculosis, malaria and hepatitis C. Launched in 2020, the task has reached the preclinical level. for long-acting medicines, with a particular focus on accessibility in low- and middle-income countries (LMICs). The $7. 9 million extension investment will support a variety of activities, adding pharmacometric tool progression, implementation research, collaboration with the Medicines Patent Pool, exploration of production capabilities, and the status quo of a practice network. Professors Owen and Rannard expressed enthusiasm for advancing long-time applicants to Humanities Studies, while university leaders highlighted the interdisciplinary nature and global effect of CELT’s work. In addition, the CELT/LONGEVITY team plans to make a contribution to the Liverpool City Area Life Sciences Investment Zone, with the aim of attracting more innovation and task creation.
(PRESS RELEASE) LIVERPOOL, April 3, 2024 — /EuropaWire/ — Unitaid has awarded more than £6 million in new investment to a task led by the University of Liverpool on long-acting remedies available to treat or save tuberculosis and malaria and hepatitis C.
The LONGEVITY project started in 2020 and has already achieved preclinical evidence of the concept of long-acting drugs for tuberculosis and for the treatment of hepatitis C virus. The main motivation of the LONGEVITY researchers is to make sure that these treatments are readily available in low-income countries. and middle-income countries (LMICs).
LONGEVITY is a component of the University of Liverpool’s Centre of Excellence for Long-Acting Therapeutics (CELT), a cross-faculty research initiative that combines cutting-edge expertise in pharmacology and tissue chemistry and works with foreign components to disseminate the results of long-term studies. -Action medicine and replace the global landscape of drug administration.
This $7. 9 million extension investment will enable a number of additional activities to ensure that CELT continues to respond to the expressed desires and opportunities held in LMIC contexts, including:
Professor Andrew Owen, Principal Investigator of the LONGEVITY task and co-director of CELT, said: “We are proud to collaborate with our passionate and committed colleagues at Unitaid on the further implementation of the LONGEVITY task. Long-acting medicines hold great promise for addressing the challenging situations of infectious disease treatment and prevention in low- and middle-income countries. The additional investment in CELT will enable us to comprehensively address the demanding situations related to equitable progression and deployment of long-acting medicines.
Professor Steve Rannard, textile chemist and co-director of CELT, said: “The opportunity to work with Unitaid and our global partners in the LONGEVITY consortium to address unfulfilled medical wishes is a great privilege. We are very excited to move into the next phase of the program and demonstrate the benefits of our long-time applicants in human studies.
Professor Wiebe Van Der Hoek, Executive Vice-Chancellor of the Faculty of Science and Engineering, said: “The CELT team has now secured an extension to scale up long-acting injectables against tuberculosis and hepatitis C infection, while exploratory work with microarrays will be initiated. What is particularly interesting about the work of CELT is its interdepartmental and even cross-faculty nature. demonstrating the benefits of multidisciplinary activities combined with a compelling team vision, generating perfect research effects and wonderful effects across fitness benefits around the world.
Professor Louise Kenny, Executive Vice-Provost of the Faculty of Health and Life Sciences, said: “We are exceptionally proud of the UNITAID-funded longevity programme and the CELT team. In fact, this work is at the forefront of drug administration. The innovation and its effect are astonishing; Long-acting drug delivery systems are proving to be a key line of defense against global threats such as antimicrobial resistance (AMR) and to address the past unmet desires of vulnerable populations. This program reaches colleagues across the university and is an inspiring, world-class example of the best of science in interdisciplinary teams.
Professor Tariq Ali, Vice-Chancellor for Global Engagement and Partnerships at the University of Liverpool, said: “I am very pleased and proud that, in combination with foreign partners, CELT will be able to continue this critical work to improve access to long-term policies. “Longevity’s task and its significant impact on the lives of people around the world make a fundamental contribution to the University of Liverpool’s global strategic ambitions.
The CELT/LONGEVITY team is planning its participation in the Liverpool City Area Life Sciences Investment Zone. It is the second largest investment zone in the UK and aims at the capacity and amenities to attract more foreign investment, drive innovation and create more than 4,000 jobs.
Media Contacts:
SOURCE: University of Liverpool
MORE ABOUT THE UNIVERSITY OF LIVERPOOL ETC. : The University of Liverpool and Sumy State University celebrate a milestone in their two-year partnership with a twinning demonstration and educational networking occasion Uncovering the past: The Church of England and the University of Liverpool collaborate to explore the ancient role in slavery University of Liverpool appoints new Chair of Oncology to tackle cancer emergence in Liverpool city region University of Liverpool VISION Group secures £569,000 for cancer care in disabled people visual impairment related to brain injuries and neurological conditions. The University of Liverpool joins a US experiment into quantum physics and the mysteries of darkness. MatterTackling lack of food confidence among workers: University of Liverpool research and progression efforts Law School Advocacy University of Liverpool student wins Wellcome Trust career progression award for research into coronavirus replication mechanisms and diversity £1. 5m commitment boosts law studies collaboration between University of Liverpool and NIMHANS In India, University of Liverpool law students provide flexible legal advice to St Chads Health Center
EuropaWire (EW) is, in fact, the first pan-European press release and press release distribution service for Europe and the European Union, which aims to consolidate Europe’s global voice of news agencies and media. Submission forms, flexible PR pricing and budgets, granular targeting, unlimited maximum success across countries, markets, verticals, industries, audiences, languages, etc. , translation and localization for greater impact on local PR, in-depth distribution. . reports, metrics, and insights, adding measured PR success, reads, interactions, impact, etc. , with no limits on words, images, and multimedia to accompany your post, among other things. Your press releases will be among the press releases of Europe’s largest and most important companies, brands and stores.
HOW DO I GET STARTED?